|
Adjust Font Size:
 
|
 The MiStent® SES is an investigational drug-eluting stent in the clinical stage of development that has been designed to optimize healing. Read more.
 Euro - PCR Meeting, May 15, 2012
Presentation: DESSOLVE I: Twelve Month Clinical and Imaging Results from the FIH Trial of the MiStent® Sirolimus Eluting Absorbable Polymer Coronary Stent System Presentation: Assessment of vascular response at 4, 6 and 8 months after the implantation of absorbable-coated sirolimus-eluting stents: an optical coherence tomography sub-study from the first-in-man DESSOLVE I trial
|
 |
 November 8, 2011 — Micell Technologies Announces Positive Preliminary Data from DESSOLVE I Study of MiStent® Sirolimus Drug Eluting Coronary Stent System
Read more. November 2, 2011 — Micell Technologies Announces Presentation of Clinical Data at TCT 2011
Read more. |
|
 Micell Technologies is bringing together the clinical advantages of a drug-eluting stent with the long-term safety and stability of a bare metal stent. The resulting drug-delivery device is intended to redefine the field of interventional cardiology. Read more.
|
|